top of page

Search

MUVON Minute: First manifesto for SUI policy reform signed

Muvon
Dec 12, 2023
0 min read

Recent Posts

MUVON Completes Patient Enrollment of Randomized Phase 2 Clinical Study Evaluating Muscle Precursor Cell (MPC)-based Therapy in Stress Urinary Incontinence and Expects Topline Data in Q3 2025

UVON Therapeutics AG, an innovative clinical-stage biotechnology company, announces dosing of the last patient in its phase 2 clinical study.

MUVON Therapeutics Clears Phase 2 Interim Milestone and Will Participate in the 2025 J.P. Morgan Healthcare Conference

MUVON Therapeutics Clears Phase 2 Interim Milestone and Will Participate in the 2025 J.P. Morgan Healthcare Conference

MUVON featured in PharmaBoardroom Interview

MUVON featured in PharmaBoardroom Interview

Comments

bottom of page